Johnson & Johnson is in talks to acquire Shockwave Medical, The Wall Street Journal reported Tuesday, citing people familiar with the matter.
A deal could come in the next few weeks. However, the report noted that talks could fall through, or another company could pick up Shockwave. J&J and Shockwave both told MedTech Dive they do not comment on market rumors or speculation.
Shockwave makes medical devices that break up calcium deposits in coronary arteries using sound pressure waves, a technique called intravascular lithotripsy (IVL).
BTIG analyst Marie Thibault called out IVL as a commercial monopoly in the medical device category that could attract buyers this year, with a pickup in medtech M&A expected in general.
The WSJ report is the latest rumor of a Shockwave acquisition: Bloomberg reported last April that Boston Scientific was looking to buy Shockwave, and StreetInsider reported in May that the company was receiving attention from other suitors.
A Shockwave deal would be a second sizable acquisition for J&J in as many years, after the company shelled out $16.6 billion for heart device maker Abiomed in late 2022. Shockwave has a market cap of more than $12 billion, according to Nasdaq.
The company reported revenue of $730.2 million in 2023, year-over-year growth of 49%. Shockwave forecasts a 2024 revenue range of from $910 million to $930 million.
Leerink Partners analysts wrote in a note to investors that “we see clear rationale to support strategic interest in [Shockwave,] with the company’s best-in-class product portfolio focused on intravascular lithotripsy (IVL) helping to bolster [J&J] (or others’) presence in interventional cardio.”
Needham analysts were enthusiastic about Shockwave in a February note, writing that the company’s IVL technology increased access to treatment for calcified lesions and “opened an $8.5B+ market that is only 6% penetrated.”
Shockwave’s stock closed up 10% at $316.07 on Tuesday following the WSJ report.
by Ricky Zipp
Source: medtechdive.com
The United Arab Emirates (UAE) Ministry of Health and Prevention (MoHAP) has established a partnership with Novo Nordisk Pharma Gulf focusing on the creation of a national scientific guide for obesity management and weight control. The collaboration also aims to enhance public awareness of cardiovascular diseases and their complications.
Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in obesity. Under the deal, the companies will use Haya’s proprietary regulatory genome discovery platform to identify and validate long non-coding RNA (lncRNA) targets for developing potential treatments for obesity and related metabolic disorders.
The sale includes custom formulation and contract manufacturing capabilities for the nutrition market from the production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico. Financial terms of the transaction were not disclosed.
